csirt@kutim:~/threat-intel/cve/CVE-2025-71422

Katalog CVE

CVSS 5.7 · Medium EPSS 0,07%

Kerentanan Improper Verification of Cryptographic Signature. Skor CVSS 3.1 5.7 (Medium) menurut vulncheck.com.

Deskripsi (NVD)

Contrast is a Kubernetes runtime for confidential containers. In versions before 1.12.1, the secure persistent volume feature is vulnerable to a malicious host supplying a crafted LUKS2 volume to a pod VM. LUKS2 volume metadata is not authenticated and, with cryptsetup versions prior to 2.8.1, a header specifying the null keyslot encryption algorithm (cipher_null-ecb) is accepted without error. Because the Contrast Initializer assumes a device is protected if `cryptsetup open` succeeds with the secret seed, the guest will open the attacker-supplied volume and write secret data in plaintext, or under a volume key known to the attacker, allowing the host to read confidential data that should have been encrypted. Contrast v1.12.1 ships cryptsetup 2.8.1, which disables null ciphers in keyslots when the passphrase is non-empty; v1.13.0 adds detached-header validation in guest memory and integrity protection for secure persistent storage. Contrast persistent volumes were not integrity protected, so integrity impact is not considered.

Rincian

Terbit di NVD
27 September 2026
Terakhir diubah
8 Oktober 2026
Status NVD
Deferred
CVSS 3.1
5.7 (Medium), sumber vulncheck.com
CVSS:3.1/AV:A/AC:L/PR:L/UI:N/S:U/C:H/I:N/A:N · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-347: Improper Verification of Cryptographic Signature
EPSS (30 hari)
0,07% peluang dieksploitasi; lebih tinggi dari 0,0% CVE lain

Produk dan versi terdampak

NVD belum mencantumkan data produk (CPE) untuk CVE ini. Produk yang terdampak biasanya disebut di deskripsi dan di advisory vendor pada daftar referensi.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 9 Okt 2026, 06:25 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.